Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.53 |
| ▸ | IL1RN | P18510 | 3/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 7/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.47 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218493 | 0.93 | EDNRA (0.56) | EDNRAERAP2IL1RNERAP1KISS1R | |
| SCHEMBL30874380 | 0.92 | EDNRA (0.58) | EDNRAERAP2IL1RNERAP1BACE1 | |
| SCHEMBL30721568 | 0.91 | EDNRA (0.60) | EDNRAERAP2IL1RNERAP1BACE1 | |
| SCHEMBL2468359 | 0.90 | GHSR (0.55) | EDNRANPBWR1GLP1R | |
| SCHEMBL30293823 | 0.89 | EDNRA (0.60) | EDNRAERAP2IL1RNERAP1BACE1 | |
| SCHEMBL2193967 | 0.89 | BACE1 (0.51) | EDNRAERAP2IL1RNERAP1BACE1 | |
| SCHEMBL30054135 | 0.88 | EDNRA (0.58) | EDNRAERAP2IL1RNERAP1BACE1 | |
| SCHEMBL16063027 | 0.87 | GLP1R (0.55) | EDNRAERAP2BACE1CTSBCTSK | |
| SCHEMBL31098013 | 0.85 | EDNRA (0.61) | EDNRAERAP2IL1RNERAP1KISS1R | |
| SCHEMBL29634678 | 0.85 | GLP1R (0.59) | BACE1KISS1RNPBWR1MAGI3GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | EDNRA 37/4885ERAP2 427/4885IL1RN 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.